First Time Loading...

MaxCyte Inc
LSE:MXCT

Watchlist Manager
MaxCyte Inc Logo
MaxCyte Inc
LSE:MXCT
Watchlist
Price: 299 GBX -1.97% Market Closed
Updated: Apr 25, 2024

Intrinsic Value

MXCT's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. [ Read More ]

The intrinsic value of one MXCT stock under the Base Case scenario is 228 GBX. Compared to the current market price of 299 GBX, MaxCyte Inc is Overvalued by 24%.

Key Points:
MXCT Intrinsic Value
Base Case
228 GBX
Overvaluation 24%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
MaxCyte Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling MXCT stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
MaxCyte Inc

Provide an overview of the primary business activities
of MaxCyte Inc.

What unique competitive advantages
does MaxCyte Inc hold over its rivals?

What risks and challenges
does MaxCyte Inc face in the near future?

Summarize the latest earnings call
of MaxCyte Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for MaxCyte Inc.

Provide P/S
for MaxCyte Inc.

Provide P/E
for MaxCyte Inc.

Provide P/OCF
for MaxCyte Inc.

Provide P/FCFE
for MaxCyte Inc.

Provide P/B
for MaxCyte Inc.

Provide EV/S
for MaxCyte Inc.

Provide EV/GP
for MaxCyte Inc.

Provide EV/EBITDA
for MaxCyte Inc.

Provide EV/EBIT
for MaxCyte Inc.

Provide EV/OCF
for MaxCyte Inc.

Provide EV/FCFF
for MaxCyte Inc.

Provide EV/IC
for MaxCyte Inc.

Show me price targets
for MaxCyte Inc made by professional analysts.

What are the Revenue projections
for MaxCyte Inc?

How accurate were the past Revenue estimates
for MaxCyte Inc?

What are the Net Income projections
for MaxCyte Inc?

How accurate were the past Net Income estimates
for MaxCyte Inc?

What are the EPS projections
for MaxCyte Inc?

How accurate were the past EPS estimates
for MaxCyte Inc?

What are the EBIT projections
for MaxCyte Inc?

How accurate were the past EBIT estimates
for MaxCyte Inc?

Compare the revenue forecasts
for MaxCyte Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of MaxCyte Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of MaxCyte Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of MaxCyte Inc compared to its peers.

Compare the P/E ratios
of MaxCyte Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing MaxCyte Inc with its peers.

Analyze the financial leverage
of MaxCyte Inc compared to its main competitors.

Show all profitability ratios
for MaxCyte Inc.

Provide ROE
for MaxCyte Inc.

Provide ROA
for MaxCyte Inc.

Provide ROIC
for MaxCyte Inc.

Provide ROCE
for MaxCyte Inc.

Provide Gross Margin
for MaxCyte Inc.

Provide Operating Margin
for MaxCyte Inc.

Provide Net Margin
for MaxCyte Inc.

Provide FCF Margin
for MaxCyte Inc.

Show all solvency ratios
for MaxCyte Inc.

Provide D/E Ratio
for MaxCyte Inc.

Provide D/A Ratio
for MaxCyte Inc.

Provide Interest Coverage Ratio
for MaxCyte Inc.

Provide Altman Z-Score Ratio
for MaxCyte Inc.

Provide Quick Ratio
for MaxCyte Inc.

Provide Current Ratio
for MaxCyte Inc.

Provide Cash Ratio
for MaxCyte Inc.

What is the historical Revenue growth
over the last 5 years for MaxCyte Inc?

What is the historical Net Income growth
over the last 5 years for MaxCyte Inc?

What is the current Free Cash Flow
of MaxCyte Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for MaxCyte Inc.

Financials

Balance Sheet Decomposition
MaxCyte Inc

Current Assets 214.3m
Cash & Short-Term Investments 190.3m
Receivables 8.2m
Other Current Assets 15.8m
Non-Current Assets 52.4m
Long-Term Investments 18.4m
PP&E 33.3m
Other Non-Current Assets 700k
Current Liabilities 16.6m
Accounts Payable 400k
Accrued Liabilities 10.6m
Other Current Liabilities 5.6m
Non-Current Liabilities 16.8m
Other Non-Current Liabilities 16.8m
Efficiency

Earnings Waterfall
MaxCyte Inc

Revenue
38m USD
Cost of Revenue
-4.7m USD
Gross Profit
33.3m USD
Operating Expenses
-80.3m USD
Operating Income
-47m USD
Other Expenses
9.5m USD
Net Income
-37.5m USD

Free Cash Flow Analysis
MaxCyte Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

MXCT Profitability Score
Profitability Due Diligence

MaxCyte Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Revenue Growth Forecast
Negative 1-Year Revenue Growth
Negative ROE
26/100
Profitability
Score

MaxCyte Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

MXCT Solvency Score
Solvency Due Diligence

MaxCyte Inc's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
High Altman Z-Score
74/100
Solvency
Score

MaxCyte Inc's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MXCT Price Targets Summary
MaxCyte Inc

Wall Street analysts forecast MXCT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MXCT is 765.99 GBX with a low forecast of 573.98 GBX and a high forecast of 937.69 GBX.

Lowest
Price Target
573.98 GBX
92% Upside
Average
Price Target
765.99 GBX
156% Upside
Highest
Price Target
937.69 GBX
214% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

MXCT Price
MaxCyte Inc

1M 1M
-13%
6M 6M
+22%
1Y 1Y
-24%
3Y 3Y
-65%
5Y 5Y
+59%
10Y 10Y
+291%
Annual Price Range
299
52w Low
210
52w High
420
Price Metrics
Average Annual Return 74.68%
Standard Deviation of Annual Returns 176.49%
Max Drawdown -83%
Shares Statistics
Market Capitalization 309.5m GBX
Shares Outstanding 104 130 000
Percentage of Shares Shorted
N/A

MXCT Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

MaxCyte Inc Logo
MaxCyte Inc

Country

United States of America

Industry

Life Sciences Tools & Services

Market Cap

309.5m GBP

Dividend Yield

0%

Description

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Gaithersburg, Maryland. The company went IPO on 2016-03-29. The firm is focused on providing enabling platform technologies to advance cell-based research and development, as well as next-generation cell therapeutic discovery, development and commercialization. The firm has developed and commercialized its Flow Electroporation platform, which facilitates complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address the cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. Its ExPERT platform consists of three instruments, which are known as the ATx, STx and GTx. The firm has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.

Contact

MARYLAND
Gaithersburg
22 Firstfield Road, Suite 250
+13015175556.0
https://www.maxcyte.com/

IPO

2016-03-29

Employees

-

Officers

President, CEO, Secretary & Director
Mr. Maher Masoud
Founder
Mr. Douglas Arthur Doerfler
Chief Financial Officer
Mr. Douglas J. Swirsky CFA, CPA
Senior Vice President of Operations
Mr. Jay Gelfman
Executive Vice President of Administration
Mr. Ronald Evan Holtz CPA, Ph.D.
Director of Investor Relations
Mr. Sean Menarguez
Show More
Senior Vice President & General Counsel
Mr. David Sandoval
Executive Vice President of Global Sales
Mr. Thomas Michael Ross
Vice President of Corporate Development
Mr. Jack Horgan
Senior Vice President of Human Resources
Ms. Jill Mayer
Show Less

See Also

Discover More
What is the Intrinsic Value of one MXCT stock?

The intrinsic value of one MXCT stock under the Base Case scenario is 228 GBX.

Is MXCT stock undervalued or overvalued?

Compared to the current market price of 299 GBX, MaxCyte Inc is Overvalued by 24%.